EP 3353197 A4 20181114 - METHOD OF REDIRECTING T CELLS TO TREAT HIV INFECTION
Title (en)
METHOD OF REDIRECTING T CELLS TO TREAT HIV INFECTION
Title (de)
VERFAHREN ZUR UMLEITUNG VON T-ZELLEN ZUR BEHANDLUNG VON HIV-INFEKTION
Title (fr)
MÉTHODE DE RÉACHEMINEMENT DE LYMPHOCYTES T POUR LE TRAITEMENT D'UNE INFECTION PAR LE VIH
Publication
Application
Priority
- US 201562222132 P 20150922
- US 201562253790 P 20151111
- US 2016053097 W 20160922
Abstract (en)
[origin: WO2017053556A1] The present invention relates to compositions and methods for treating of a HIV infected mammal using a CD4 membrane-bound chimeric receptor or a HIV specific scFvs CARs. One aspect includes a modified T cell and pharmaceutical compositions comprising the modified cells for adoptive cell therapy and treating a disease or condition associated with HIV infection.
IPC 8 full level
C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 19/00 (2006.01)
CPC (source: EP KR US)
A61K 35/17 (2013.01 - US); A61K 38/1774 (2013.01 - EP US); A61K 39/42 (2013.01 - US); A61K 39/4611 (2023.05 - EP KR); A61K 39/4631 (2023.05 - EP KR); A61K 39/464838 (2023.05 - EP KR); A61K 45/06 (2013.01 - US); A61P 31/18 (2017.12 - EP US); C07K 14/705 (2013.01 - KR); C07K 14/7051 (2013.01 - EP KR US); C07K 14/70514 (2013.01 - EP KR US); C07K 14/70517 (2013.01 - EP US); C07K 14/70521 (2013.01 - EP KR US); C07K 14/70578 (2013.01 - EP US); C07K 16/1045 (2013.01 - KR US); C12N 5/0636 (2013.01 - EP KR); A61K 2039/505 (2013.01 - US); A61K 2039/5158 (2013.01 - US); A61K 2039/572 (2013.01 - US); C07K 2317/21 (2013.01 - US); C07K 2317/24 (2013.01 - US); C07K 2317/622 (2013.01 - US); C07K 2317/76 (2013.01 - US); C07K 2319/00 (2013.01 - EP KR US); C07K 2319/02 (2013.01 - EP KR US); C07K 2319/03 (2013.01 - EP KR US); C07K 2319/30 (2013.01 - US); C07K 2319/33 (2013.01 - EP US); C12N 2510/00 (2013.01 - KR)
Citation (search report)
- [Y] US 2014271635 A1 20140918 - BROGDON JENNIFER [US], et al
- [X] LIU LI ET AL: "Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 89, no. 13, 1 July 2015 (2015-07-01), pages 6685 - 6694, XP008177657, ISSN: 0022-538X, [retrieved on 20150415], DOI: 10.1128/JVI.00474-15
- [Y] M. J. FRIGAULT ET AL: "Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells", CANCER IMMUNOLOGY RESEARCH, vol. 3, no. 4, 19 January 2015 (2015-01-19), US, pages 356 - 367, XP055271039, ISSN: 2326-6066, DOI: 10.1158/2326-6066.CIR-14-0186
- [T] RACHEL S. LEIBMAN ET AL: "Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor", PL O S PATHOGENS (PRINT), vol. 13, no. 10, 12 October 2017 (2017-10-12), US, pages e1006613, XP055509157, ISSN: 1553-7366, DOI: 10.1371/journal.ppat.1006613
- See references of WO 2017053556A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2017053556 A1 20170330; AU 2016326500 A1 20180412; BR 112018005741 A2 20181009; CA 2999496 A1 20170330; CL 2018000750 A1 20181228; CN 108779161 A 20181109; EA 201890782 A1 20180928; EP 3353197 A1 20180801; EP 3353197 A4 20181114; IL 258191 A 20180531; JP 2018527014 A 20180920; JP 6991131 B2 20220203; KR 20180050413 A 20180514; MA 42951 A 20180801; MX 2018003463 A 20180906; PH 12018500609 A1 20181001; US 10738099 B2 20200811; US 2018265565 A1 20180920; US 2020362012 A1 20201119
DOCDB simple family (application)
US 2016053097 W 20160922; AU 2016326500 A 20160922; BR 112018005741 A 20160922; CA 2999496 A 20160922; CL 2018000750 A 20180321; CN 201680066602 A 20160922; EA 201890782 A 20160922; EP 16849585 A 20160922; IL 25819118 A 20180318; JP 2018515108 A 20160922; KR 20187011293 A 20160922; MA 42951 A 20160922; MX 2018003463 A 20160922; PH 12018500609 A 20180321; US 201615761563 A 20160922; US 202016988415 A 20200807